Furosemide-induced atypical toxic epidermal necrolysis

Authors

  • Ana María Tierra-Rodríguez Servicio de Medicina Interna, Hospital El Bierzo, Ponferrada (León), Spain
  • Beatriz López-Prada Servicio de Urgencias, Hospital El Bierzo, Ponferrada (León), Spain
  • Ángel Fernández-Díaz Servicio de Neurología, Hospital El Bierzo, Ponferrada (León), Spain

DOI:

https://doi.org/10.32818/reccmi.a4n1a4

Keywords:

toxic epidermal necrolysis, Stevens-Johnson syndrome, furosemide.

Abstract

Toxic epidermal necrolysis is a rare and severe skin disease, usually induced by drugs, that is characterized by an epidermal detachment that affects more than 30% of the total body surface. It is very important to keep it in mind, for the risk of secondary complications and high mortality. Furosemide is a diuretic of the sulfonamide group, widely used in daily clinical practice, which rarely produces this type of adverse reaction. We present an atypical clinical case of toxic epidermal necrolysis induced by furosemide. It differs from previous cases in the form of presentation, diagnosis and evolution.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Gallardo Rivera CE, Souza Suárez-Medrano AG, Domínguez Borgua A, Gutiérrez Sánchez CO, Cruz Martínez RZ, Medina Navarro OA. Necrólisis epidérmica tóxica asociada a uso de furosemida. Reporte de caso y breve revisión de la literatura. Dermatología CMQ. 2017; 15(2): 84-89.

García-Doval I, Roujeau JC, Cruces Prado MJ. Necrólisis epidérmica tóxica y síndrome de Stevens-Johnson: clasificación y actualidad terapéutica. Actas Dermosifiliogr. 2000; 91: 541-551.

Wright AA, Vesta KS, Stark JE, Smith WJ. Stevens-Johnson syndrome as- sociated with furosemide: a case report. J Pharm Pract. 2010 Aug; 23(4): 367-370. doi: https://doi.org/10.1177/0897190010362260.

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan; 129(1): 92-96.

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14; 333(24): 1600-1607.

Melloni Magnelli L, Padrón Flores AE, Larrazábal Aguerrevere LI, Sony Avendaño BN. Necrólisis epidérmica tóxica inducida por fármacos. Caso clínico. Cir. Plást. Iberolatinoam. 2008; 34(4): 305-312.

Abe J, Mataki K, Umetsu R, Ueda N, Kato Y, Nakayama Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013. Allergol Int. 2015 Jul; 64(3): 277-279. doi: https://doi.org/10.1016/j.alit.2015.01.002.

Osuna Osuna J, Toledo Bahena ME, Valencia Herrera A, Ramírez Cortés E, Mena Cedillos C. Reacción por drogas con eosinofilia: síndrome DRESS, un gran simulador. Dermatología Cosmética Médica y Quirúrgica. 2013; 11(2). Accesible en: https://dcmq.com.mx/edici%C3%B3n-abril-junio-2013-volumen-11-n%C3%BAmero-2/154-reaccion-por-drogas-con-eosinofilia-sindrome-dress-un-gran-simulador.html

Yuste M, Sánchez-Estella J, Santos JC, Alonso MT, Bordel MT, Gutiérrez JL, et al. Síndrome de Stevens-Johnson/necrólisis epidérmica tóxica tratado con inmunoglobulinas intravenosas. Actas Dermosifiliogr. 2005 Nov; 96(9): 589-592.

Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspecti- ves on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018 Feb; 54(1): 147-176. doi: https://doi.org/10.1007/s12016-017-8654-z.

Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun; 174(6): 1194-1227. doi: https://doi.org/10.1111/bjd.14530.

Published

2019-04-30

How to Cite

1.
Tierra-Rodríguez AM, López-Prada B, Fernández-Díaz Ángel. Furosemide-induced atypical toxic epidermal necrolysis. Rev Esp Casos Clin Med Intern [Internet]. 2019 Apr. 30 [cited 2024 Jul. 22];4(1):10-2. Available from: https://www.reccmi.com/RECCMI/article/view/341